Gene Therapy Development 2024

13 - 14 June 2024 | London, UK

Join leaders at the forefront of gene therapy development, offering insights on navigating the latest advancements and challenges in gene therapy production.

Presentation Speaker

Explore Gene Therapy Development 2024: Unlocking Future Insights in Gene Therapy Development Research

The 3rd Annual Gene Therapy Development Congress unites leading experts working in gene therapy development to provide a comprehensive journey through the latest advances and challenges, with the aim of accelerating gene therapy production.

3rd Annual Gene Therapy Development Congress

Gain an end-to-end outlook on the entire journey of gene therapy development, with 5 tracks exploring the discovery, clinical trial, manufacturing, and commercialisation of gene therapies.

Tackle the latest challenges in our interactive sessions featuring panel discussions and roundtables, addressing pressing issues such as vector design, gene engineering, preparing for regulatory changes, and more

Benefit from real-world case studies presented by industry experts, including insights into how to navigate regulatory submission, as well as operationalising clinical trials

Acquire practical solutions to overcome obstacles in the development and production of gene therapies, with opportunities to meet with and hear from vendor companies

Agenda at a Glance


  • Day One, Track 1: Vector Development
  • Day One, Track 2: Gene Therapy Manufacturing & Supply Chain 
  • Day One, Track 3: Pre-clinical and Clinical Therapeutic Development
  • Day Two, Track 1: Gene Therapy Analytics
  • Day Two, Track 2: Emerging Targets and Gene Editing Tools and Strategies

What to Expect

250

leading pharma, biotech, & academic delegates

15
hours of presentations, discussions & interactive content
7
hours of networking breaks, including speed networking & refreshments
80
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 45 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

Gene Therapy Development 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Alba Guijarro Belmar
Head of Vector Development,
Sania Therapeutics
Avencia Sanchez-Mejias
CEO and Co-Founder,
Integra Therapeutics
Nathalie Cartier-Lacave
Vice President Neurobiology,
AskBio
Nuno Barata
Global Medical Director,
Novartis Gene Therapies
Victor Ferrero
Associate Director, Global Product Strategy,
BioMarin

All Speakers

Alberto del Rio Espinola
Director,
GentiBio Inc
Amin Hajitou
Professor, Reader in Neuroinflammation,
Imperial College London
Breech Conrad Odu
Process Development Scientist,
Merck Life Sciences
Charlotte Smerdon
Senior Director, Clinical Operations,
Purespring Therapeutics
Claire Kerridge
Head of Gene Therapy,
MHRA
Claudio Mussolino
Group Leader,
Medical Center - University of Freiburg
Elina Hessels
Associate Director Analytical Platforms,
uniQure
Ellina Allais
Regulatory Affairs Senior Director,
Cellectis S.A.
Eugenio Macchiarulo
Director MSAT,
Barinthus Bio
Giandomenico Turchiano
Associate Director,
UCL/AstraZeneca
Isabelle Richard
Director of Research,
Genethon
James Norton
Director Analytical Development,
MeiraGTx
Jane Kinghorn
Director Translational Research Office,
University College London
Johnson Varghese
VP, Head of Analytical Research and Development,
Beam Therapeutics
Julia Berretta
CEO,
Genespire
Khalid Saeed
Senior scientist,
AstraZeneca
Koval Smith
Senior Manager DS/DP MSAT,
Orchard Therapeutics
Laurence Guianvarc'h
Head of Upstream & Downstream Process Development,
Nantes University
Lilian Hook
Director Cell, Apheresis and Gene Therapies,
NHS Blood and Transplant
Michel Degueldre
Lead GT Biophysical Sciences,
UCB
Nathalie Uzcategui
Senior Scientist,
Hansa BioPharma
Nina Kotsopoulou
,
AAVantgarde Bio
Otmane Boussif
Chief Technology Officer,
Anjarium Biosciences
Pamela Whalley
Associate Director CMC,
Complementtx
Patricia Lareo
Value Chain Capability Lead Gene Therapy,
Roche
Paul Carter
Senior Director MSAT,
Quell Therapeutics
Peter Pechan
Head of Vector Biology and Discovery,
UCB Biosciences
Rodolphe Clerval
CEO,
Coave Tx
Senior Representative
,
AviadoBio
Simon Eaglestone
Director, Program Management,
Bloomsburygtx
Victor Dillard
VP, Strategy & Operations,
Resolution Therapeutics
Vinciane De Cupere
Technical Lead Gene Therapy,
UCB
Yu-Tsan (Richard) Liu
Sr. Scientist,
UCB Pharma

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Enhancing Gene Editing Efficiency: Multi-Tailed mRNA Integration in CRISPR-Cas9 Systems

A study conducted by the Broad Institute and the Massachusetts Institute of Technology (MIT) demonstrated that when multi-tailed mRNAs were integrated into a CRISPR-Cas9 system they proved to be more efficient gene editors than unmodified mRNA.

Cell Therapy for Solid Tumors: An Innovative Approach to Cancer Treatment

Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.

Post-Event Proceedings – Gene Therapy Development & Manufacturing 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Gene Therapy Development & Manufacturing 2023.

Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.

Spotlight On: Lindsay Davies, Chief Scientific Officer of NextCell Pharma

We caught up with Lindsay Davies, Chief Scientific Officer of NextCell Pharma, to hear about to hear about the latest advancements in stromal cell therapy in anticipation of her presentation at our Cell & Gene 2024 Congress this November.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Plan Your Visit

ILEC Conference Centre
47 Lillie Rd London SW6 1UD United Kingdom

By Underground

Sitting at the edge of zone 1, West Brompton and Earls Court stations are both within walking distance giving easy access to all central districts of London and Heathrow Airport. Transport for London tube map.

By Car

ILEC is a quarter of a mile (400m) from the A4, providing easy access to the M4, M5 and M40.

By Air

Heathrow (LHR): 21 km - Approximately 30 minutes in light traffic. You can also reach the airport directly by London Underground, on the Piccadilly line. Gatwick (LGW): 45 Km - Approximately an hour in light traffic. It is 40 minutes by train from West Brompton station via Clapham Junction. Direct shuttle available with Easy Bus. London City (LCY): 21 km - Approximately 45 minutes in light traffic.

Parking

There is a car park adjacent to ILEC with 140 parking bays. The parking is NOT managed by ILEC so spaces cannot be reserved and may become full during busy events. Guests and delegates can benefit from preferential parking rates as follows: Up to 2 hours £7 Up to 4 hours £11 Up to 6 hours £14 Up to 9 hours £16 (£21 for non-residents) Up to 12 hours £20 (£26 for non-residents) Up to 24 hours (overnight) £26

Oxford Global have secured a number of bedrooms at ibis London Earls Court at a reduced rate:

 

Wednesday 12th June 2024 – £176, breakfast included

Thursday 13th June 2024 – £176, breakfast included

 

Should you wish to book a room, please email help@oxfordglobal.com. The final cut-off date to book bedrooms is Monday 29th April 2024 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to cancellation charges.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Gene Therapy Development 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch